ESTRO 2024 - Abstract Book

S1740

Clinical - Lung

ESTRO 2024

Descriptive statistics of characteristic of patients who underwent surgery and radiotherapy were analysed. Progression free survival (PFS) of the 2 cohorts was calculated using Kaplan-Meir estimate as time between attendance at One-Stop Clinic and recurrence or death.

Results:

Of the 241 patients, 142 had radiotherapy, 86 had surgery and 13 patients were categorised as other.

Table 1 compares characteristics and outcomes of the 228 patients receiving radiotherapy or surgery.

4 surgical patients died within 90 days of treatment, with 3 of these dying within 30 days. No patients who received radiotherapy died within 90 days of treatment. Of the radiotherapy patients, 12 patients (8.5%) had recurrence with 4 of these dying; a further 2 patients died leading to a total of 6 patient (4.2%) deaths in this cohort. Of the surgical patients, 9 patients (10.5%) had recurrence with 4 of these dying; a further 4 surgical patients died leading to 8 patient deaths (9.3%) in this cohort.

In our data there was no significant difference in progression free survival between patients who had radiotherapy or those who had surgery, as shown in Figure 1.

Table 1: characteristics and outcomes of patients attending One-Stop

N=228

Radiotherapy

Surgery

Number

%

Number

%

Treatment

142

62.3

86

37.8%

Median age (years)

74

70

Median ppo-FEV1 %

62.2

58

Stage I

104

73.2

53

61.6

Stage II

23

16.2

18

20.9

Stage III

15

10.6

15

17.4

CFS 1-3

71

50

69

80.2

CFS 4-6

71

50

17

19.8

PS 0

8

5.6

19

22.1

PS 1

61

43

50

58.1

PS 2

68

47.9

17

19.8

PS 3

5

3.5

0

0

ILD

7

4.9

3

3.5

Current smoker

45

31.7

32

37.2

Radiotherapy regimen SABR (≤ 8#)

78

55

60Gy in 30# with chemo

4

3

55-60Gy in 15-20#

58

41